Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.77 |
| ▸ | RAB9A | P51151 | 6/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.59 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.59 |
| ▸ | SMO | Q99835 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.56 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.56 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.56 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254257 | 0.85 | NPC1 (1.00) | NPC1RAB9AMAPTKCNK3KCNK9 | |
| SCHEMBL30369807 | 0.85 | NPC1 (1.00) | NPC1RAB9AMAPTKCNK3KCNK9 | |
| SCHEMBL8203978 | 0.85 | RAB9A (1.00) | NPC1RAB9AMAPTHPGDKCNK3 | |
| SCHEMBL19156955 | 0.84 | KCNK3 (0.66) | NPC1RAB9AMAOBKCNK3KCNK9 | |
| SCHEMBL2304424 | 0.83 | L3MBTL1 (0.81) | NPC1RAB9AMAPTKCNK3MEN1 | |
| SCHEMBL3790049 | 0.82 | MAPT (0.83) | NPC1RAB9AMAPTKCNK3KCNK9 | |
| SCHEMBL4117539 | 0.81 | SLC2A1 (0.54) | NPC1RAB9AMAPTMAOBMEN1 | |
| SCHEMBL14426546 | 0.81 | NPC1 (0.73) | NPC1RAB9AMAPTKCNK3KCNK9 | |
| SCHEMBL6054992 | 0.81 | NPC1 (0.78) | NPC1RAB9AMAPTHPGDKCNK3 | |
| SCHEMBL21473657 | 0.81 | NPC1 (0.73) | NPC1RAB9AHPGDKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269814-B2 | Process for preparing a compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2025-04-08 | — | — | US | disclosed |
| US-11661415-B2 | Process for preparing a compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661415-B2 | Process for preparing a compound useful to treat mycoses | DPM1, CYP51A1, ERG28 | NPC1 713/4885RAB9A 1450/4885MAPT 2626/4885 |
| US-12269814-B2 | Process for preparing a compound useful to treat mycoses | C1R, CBR1, CBR3 | NPC1 223/4885RAB9A 1340/4885MAPT 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.